BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32620120)

  • 1. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
    Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
    Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
    BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
    Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
    BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
    Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
    BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
    Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
    Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
    Chen R; Xie L; Xue W; Ye Z; Ma L; Gao X; Ren S; Wang F; Zhao L; Xu C; Sun Y;
    Urol Oncol; 2016 Sep; 34(9):416.e1-7. PubMed ID: 27185342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
    Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
    Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer risk assessment tools in an unscreened population.
    Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
    World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
    Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
    BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
    Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
    BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
    Louie KS; Seigneurin A; Cathcart P; Sasieni P
    Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.